Burning Rock Biotech Ltd (BNR) is a pioneering precision oncology company that specializes in applying cutting-edge technologies to transform cancer diagnostics and treatment. Committed to enhancing precision medicine and personalized treatment for cancer patients, BNR operates in the rapidly evolving field of next-generation sequencing (NGS) to develop innovative cancer therapies tailored to individual patient needs.
Headquartered in Guangzhou, China, BNR was founded in 2014 and has grown with several years of dedication to genomic profiling and molecular diagnostics to fight cancer. The company has been listed on NASDAQ since June 2020, under the ticker symbol 'BNR'.
BNR's comprehensive offering includes diagnostic solutions for early cancer detection, treatment decisions, and monitoring. These solutions are delivered through three primary services: central laboratory services, in-vitro diagnostic products, and bio-banking services. As an innovative company, it continues to stay at the forefront of technology, integrating AI and data analysis with medical science.
One of the company’s flagship products is its NGS panels portfolio, with panels focusing on a variety of cancer types, including lung, gastrointestinal, and urinary cancer. BNR's NGS-based technology enables comprehensive mutation detection, providing physicians with more insight into a patient's condition.
Another notable achievement is the company's partnership with medical, scientific, and academic institutions to further research and innovation. This has facilitated the company's growth and kept it at the forefront of the precision oncology field.
In the area of early cancer detection, BNR is devoted to the development of innovative liquid biopsy technologies. Leveraging on the unique genetic profiles of different cancer types, these technologies aim to detect cancer in its early stages, dramatically improving treatment success rates.
With a visionary approach, BNR is setting a new standard in the field of oncology. The company's work has had a profound impact on the medical industry and patients' lives, making it a prominent player in the global biotech industry. Also, BNR’s unwavering commitment to precision medicine is reflected in its continuous investment in research and development, thereby ensuring the company’s innovative edge remains sharp and impactful.
In conclusion, Burning Rock Biotech Ltd is a company that exemplifies the power of cutting-edge technology and science, translating them into actionable solutions for cancer. While its focus is on precision oncology today, BNR's approach could lay the foundation for advancements across the spectrum of healthcare, making a significant impact on dealing with diseases in the future.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
This article analyzes Burning Rock Biotech Limited (NYSE: BNR), indicating weak sentiment across all time horizons and supporting a short bias. It outlines three AI-generated trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal analysis, including support and resistance levels for near-term, mid-term, and long-term horizons.
This article lists 12 healthcare stocks that experienced significant movement during Friday's pre-market session. It details the top gainers, including Apimeds Pharmaceuticals and Firefly Neuroscience, along with their percentage increases and market capitalization. The article also highlights the top losers, such as Burning Rock Biotech and Pomdoctor, providing their percentage decreases and market caps.
Insiders at Burning Rock Biotech Limited, including founder Yusheng Han, recently saw an 11% share price gain, recouping some losses from their CN¥11.6m purchases over the past year. Despite this, insiders are still down CN¥1.4m overall. Insider ownership remains strong at 31%, suggesting confidence in the company's future despite current losses.